Format

Send to

Choose Destination
Pharmacotherapy. 2009 Aug;29(8):891-905. doi: 10.1592/phco.29.8.891.

Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.

Author information

1
Hartford Hospital Drug Information Center, Hartford, Connecticut 06102-5037, USA.

Abstract

STUDY OBJECTIVE:

To assess the comparative efficacy of pharmacologic agents for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

DESIGN:

Traditional and mixed-treatment comparison (MTC) meta-analyses of randomized controlled trials.

PATIENTS:

A total of 31,020 patients with COPD from 43 trials.

MEASUREMENTS AND MAIN RESULTS:

A systematic literature search of various databases (through October 2007) was performed to identify randomized controlled trials of long-acting beta(2)-agonists, tiotropium, inhaled corticosteroids, and/or combination therapy with an inhaled corticosteroid and a long-acting beta(2)-agonist in patients with COPD. Forty-three trials were included. Both meta-analyses were used to evaluate the occurrence of one or more episodes of COPD exacerbation, overall mortality, and patient withdrawal rates. With MTC analysis, long-acting beta(2)-agonists, tiotropium, inhaled corticosteroids, and combination inhaled corticosteroid-long-acting beta(2)-agonist therapy each decreased the odds of having an exacerbation by 16%, 31%, 15%, and 24%, respectively, compared with placebo. Moreover, tiotropium use reduced the odds of having at least one exacerbation by 18% compared with long-acting beta(2)-agonists and by 19% compared with inhaled corticosteroids alone. Each of the four drug classes was associated with significant odds reductions in patient withdrawals (26-41%) compared with placebo, and both tiotropium and combination therapy significantly decreased the odds of patient withdrawals compared with long-acting beta(2)-agonists or inhaled corticosteroids alone. Only combination therapy was associated with a mortality benefit, showing a 29% reduction compared with placebo and a 25% reduction compared with long-acting beta(2)-agonists alone. Compared with combination therapy, tiotropium use reduced exacerbations by 9% and increased mortality by only 4%. These findings did not demonstrate significant changes in the sensitivity or subgroup analyses, which were performed to evaluate the effect of heterogeneity among the included studies.

CONCLUSIONS:

Combination inhaled corticosteroid-long-acting beta(2)-agonist therapy was associated with the greatest positive effect on outcomes in patients with COPD. Of the bronchodilator monotherapies, tiotropium was associated with lower odds of having a COPD exacerbation or withdrawal from a study compared with long-acting beta(2)-agonists.

PMID:
19637942
DOI:
10.1592/phco.29.8.891
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for PubMed Health
Loading ...
Support Center